ARCHIVES

DCT Advisors Approve Five Trials For High Priority Status

This article is from The Cancer Letter archive.

Vol. 21 No. 14 | April 7, 1995

Download PDF Visit The Full Archive

Related Articles

NCI Staff Finishes Center Program Study, Submits Recommendations

February 25, 1977

FDA Approves Abraxane For Second-Line Treatment Of Metastatic Breast Cancer

January 28, 2005

Hawaii Gets CBCCP Award

August 12, 1977

Phase III Tecemotide Trial Fails OS Endpoint; Second Trial Planned After Subgroup Analysis

December 27, 2013

Big Get Bigger, Litton Primate Contract Renewed

September 19, 1975

Funding and Direction of IL-2/LAK Trials Questioned By DCT Board

March 3, 1989